

1 **The Role of Cytokines in Acute and Chronic Postsurgical Pain in Pediatric Patients after**
2 **Major Musculoskeletal Surgeries**

3
4 Vidya Chidambaran (MD)^a, Qing Duan (PhD)^b, Valentina Pilipenko (PhD)^b, Susan M. Glynn
5 (BA)^a, Alyssa Sproles (BA)^c, Lisa J. Martin (PhD)^d, Michael J. Lacagnina (PhD)^a, Christopher D.
6 King (PhD)^e, Lili Ding (PhD)^b
7

8 ^aDepartment of Anesthesiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH,
9 USA Vidya.Chidambaran@cchmc.org, Susan.Glynn@cchmc.org,
10 Michael.Lacagnina@cchmc.org
11

12 ^bDivision of Biostatistics and Epidemiology, Department of Pediatrics, Cincinnati Children's
13 Hospital Medical Center, Cincinnati, OH, USA Qing.Duan@cchmc.org
14 Valentia.Pilipenko@cchmc.org Lili.Ding@cchmc.org
15

16 ^cDivision of Rheumatology, Department of Pediatrics, Cincinnati Children's Hospital Medical
17 Center, Cincinnati, OH, USA Alyssa.Sproles@cchmc.org
18

19 ^dDivision of Human Genetics, Department of Pediatrics, Cincinnati Children's Hospital Medical
20 Center, Cincinnati, OH, USA Lisa.Martin@cchmc.org
21

22 ^eDivision of Behavioral Medicine and Clinical Psychology, Department of Pediatrics, Cincinnati
23 Children's Hospital Medical Center, Cincinnati, OH, USA Christopher.King@cchmc.org
24

25 **Corresponding author:**

26 Vidya Chidambaran, MD, MS
27 Professor, Department of Anesthesia, Cincinnati Children's Hospital Medical Center
28 3333 Burnet Avenue, Cincinnati, OH, 45229, USA
29 Email: vidya.chidambaran@cchmc.org, Phone: (513) 636-4408
30

31 **Running Title:** Cytokines in Chronic/Acute Pediatric Postsurgical Pain
32

33 **Keywords:** Cytokines, Pediatric, Acute postsurgical pain, chronic postsurgical pain
34

35 **Declarations of interest:** none
36

37 **Disclosures:** Research reported in this manuscript was supported by National Institute of
38 Arthritis and Musculoskeletal and Skin Diseases under award number 5R01AR075857
39 (PI:Chidambaran). The content is solely the responsibility of the authors and does not necessarily
40 represent the official views of the National Institutes of Health.
41
42

44 **Abstract**

45 **Study Objective:** To determine if baseline cytokines and their changes over postoperative days
46 0-2 (POD0-2) predict acute and chronic postsurgical pain (CPSP) after major surgery.

47 **Design:** Prospective, observational, longitudinal nested study.

48 **Setting:** University-affiliated quaternary children's hospital.

49 **Patients:** Subjects (≥ 8 years old) with idiopathic scoliosis undergoing spine fusion or pectus
50 excavatum undergoing Nuss procedure.

51 **Measurements:** Demographics, surgical, psychosocial measures, pain scores, and opioid use
52 over POD0-2 were collected. Cytokine concentrations were analyzed in serial blood samples
53 collected before and after (up to two weeks) surgery, using Luminex bead arrays. After data
54 preparation, relationships between pre- and post-surgical cytokine concentrations with acute (%
55 time in moderate-severe pain over POD0-2) and chronic (pain score $> 3/10$ beyond 3 months post-
56 surgery) pain were analyzed. After adjusting for covariates, univariate/multivariate regression
57 analyses were conducted to associate baseline cytokine concentrations with postoperative pain,
58 and mixed effects models were used to associate longitudinal cytokine concentrations with pain
59 outcomes.

60 **Main Results:** Analyses included 3,164 measures of 16 cytokines from 112 subjects (median
61 age 15.3, IQR 13.5-17.0, 54.5% female, 59.8% pectus). Acute postsurgical pain was associated
62 with higher baseline concentrations of GM-CSF ($\beta=0.95$, SE 0.31; $p=.003$), IL-1 β ($\beta=0.84$, SE
63 0.36; $p=.02$), IL-2 ($\beta=0.78$, SE 0.34; $p=.03$), and IL-12 p70 ($\beta=0.88$, SE 0.40; $p=.03$) and
64 longitudinal postoperative elevations in GM-CSF ($\beta=1.38$, SE 0.57; $p=.03$), IFN γ ($\beta=1.36$, SE
65 0.6; $p=.03$), IL-1 β ($\beta=1.25$, SE 0.59; $p=.03$), IL-7 ($\beta=1.65$, SE 0.7, $p=.02$), and IL-12 p70
66 ($\beta=1.17$, SE 0.58; $p=.04$). In contrast, CPSP was associated with lower baseline concentration of

67 IL-8 ($\beta = -0.39$, SE 0.17; $p = .02$), and the risk of developing CPSP was elevated in patients with
68 lower longitudinal postoperative concentrations of IL-6 ($\beta = -0.57$, SE 0.26; $p = .03$), IL-8 ($\beta = -$
69 0.68, SE 0.24; $p = .006$), and IL-13 ($\beta = -0.48$, SE 0.22; $p = .03$). Furthermore, higher odds for
70 CPSP were found for females (vs. males) for IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, and TNF α , and
71 for pectus (vs. spine) surgery for IL-8 and IL-10.

72 **Conclusion:** We identified pro-inflammatory cytokines associated with increased acute
73 postoperative pain and anti-inflammatory cytokines associated with lower CPSP risk, with
74 potential to serve as predictive and prognostic biomarkers.

75

76

77 1. Introduction

78

79 Major musculoskeletal surgeries are often accompanied by acute postsurgical pain, which
80 can have deleterious effects on long-term function and recovery, leading to chronic postsurgical
81 pain (CPSP). Pectus excavatum repair and spine deformity correction surgery are two such
82 painful surgeries adolescents undergo and are associated with extensive dissection, muscle
83 derangements, inflammation, nerve sensitization [1] and CPSP [2, 3]. Surgeries are often
84 associated with a host of immune responses following tissue injury and incision [4]. These
85 include the release of cytokines, stress responses and acute phase proteins, which can be harmful
86 when excessive. [5] At the same time, these responses are the body's defense against infection
87 and tissue damage, and their release can be protective. Thus, a simple anti-inflammatory strategy
88 for example with Non-steroidal Anti-inflammatory Drugs raises concerns regarding adverse
89 effects, such as infection and delayed wound-healing[6]. Understanding how these inflammatory
90 responses impact pain outcomes is therefore important to know which cytokines may promote
91 healing and which ones are associated with harmful pain.

92 Cytokines, as pivotal regulators of immune and inflammatory processes, have emerged as
93 key players in the modulation of pain pathways.[7] Cytokines are soluble molecular substances
94 produced by inflammatory cells. Broadly, they can be either pro-inflammatory (e.g., interleukins
95 (IL)-1, 2, 8, 12; tumor necrosis factor α (TNF α), interferon γ (IFN γ)) or anti-inflammatory (e.g.
96 IL-4, IL-10, IL-13, transforming growth factor beta (TGF β)), while some such as IL-6 can be
97 both pro- and anti-inflammatory. Pro-inflammatory cytokines may be associated with
98 postoperative pain after musculoskeletal surgeries [8] and may activate neural circuits to
99 maintain hyperalgesia states [9]. Certain inflammatory profiles in the serum and body fluids have
100 been suggested to be characteristic of poorly resolving pain after joint surgery [10]. However,

101 other studies have refuted these findings and did not find associations between perioperative
102 cytokine concentrations with postoperative pain following total knee arthroplasty [11]. Thus,
103 there is a lack of understanding of the role of cytokines in acute and chronic postoperative pain.
104 This is crucial for developing targeted and effective pain management strategies, as a precise
105 understanding of the cytokine response to surgical trauma may inform interventions that would
106 optimize perioperative care, decrease morbidity and enhance recovery.

107 In this study, we aimed to investigate whether baseline cytokine profiles and longitudinal
108 concentration changes in cytokines after surgery predicted acute and chronic postoperative pain
109 outcomes. We hypothesized pro-inflammatory cytokines such as interferon gamma interferon
110 (IFN γ), IL1 β , IL2, IL8, and TNF- α will be associated with increased risk, while anti-
111 inflammatory cytokines such as IL4, IL10, and IL13 will decrease risk for poor pain outcomes
112 after surgery.

113 2. Materials and Methods

114 This prospective, observational, longitudinal study was nested within a larger genomics
115 study ([ClinicalTrials.gov](https://clinicaltrials.gov) Identifier: NCT02998138, NCT01839461, NCT01731873) and was
116 conducted at a university-affiliated quaternary children's hospital. The Cincinnati Children's
117 Institutional Review Board approved the study. Results pertaining to psychosocial factors and
118 epigenetic factors influencing CPSP have been previously published [3, 12, 13]. Written
119 informed consent was obtained from parents and assent from children before enrollment, either
120 on paper or electronically, through Research Electronic Data Capture (REDCap), a secure web
121 application for building and managing online surveys and databases. This study adhered to the
122 Reporting of Observational Studies in Epidemiology (STROBE) guidelines [14].

123

124 2.1 Participants

125 Healthy children aged 8 years and above, regardless of sex or race, were included if they
126 had a diagnosis of idiopathic scoliosis/kyphosis or pectus excavatum, American Society of
127 Anesthesiologists physical status ≤ 2 (mild systemic disease) and were scheduled for elective
128 spine fusion or Nuss procedure. They were screened from operating room schedules and
129 recruited if they satisfied inclusion/exclusion criteria. Exclusion criteria included a history of
130 opioid use in the past six months, liver and renal disease, pregnant or breastfeeding females,
131 developmental delay, cancer, and those not fluent in written and/or spoken English. Perioperative
132 management included standardized surgery-specific anesthesia and multimodal pain protocols.
133 Patients undergoing either surgery received acetaminophen and ketorolac (on postoperative day
134 (POD)0-2), dexamethasone (intraoperative only), muscle relaxants and opioids. Pectus patients
135 also received regional anesthesia, methadone and pregabalin.

136 2.2 Data collection

137 Data were collected by chart review and via questionnaires administered through
138 REDCap via email. Before surgery, the following data were collected: demographics (sex, age,
139 race), weight, pain scores (numerical rating scale (NRS) 0-10)[15], diagnosis and surgery type.
140 The Pediatric Pain Screening Tool (PPST) was administered preoperatively – a brief, 9-item self-
141 report questionnaire developed for rapid identification of risk for poor pain coping. It has been
142 validated in patients with chronic pain and within this surgical cohort for CPSP risk stratification
143 [12, 16]. The first four items evaluate physical symptoms, and the next four questions evaluate
144 psychosocial constructs. PPST total scores range from 0 to 9. Perioperative data collected
145 included duration of surgery, pain scores (recorded every four hours) and analgesia (opioid
146 medications/doses, (intravenous, oral and patient-controlled analgesia) over 48 hours after
147 surgery. After hospital discharge, questionnaires were administered via REDCap 3-6 and 10–12
148 months after surgery to obtain pain measures (average and maximum pain scores over the last
149 week).

150

151 2.2.1 Blood draws

152 Blood was collected from intravenous catheters placed for clinical purposes and /or
153 indwelling lines. An 8 ml sample was collected in purple top/EDTA tubes at baseline. Additional
154 samples (1-2 ml) were collected at the scheduled time-points (**Figure 1**). The total amount of
155 blood drawn per patient was approximately 30 ml. Whole blood samples were centrifuged at
156 3500 rpm for 10 minutes, plasma aliquoted into two tubes (minimal volume per freezer aliquot
157 tube: 250 microliters) and stored at -80°C until analysis.

158 2.2.2 Postoperative pain outcomes

159 Acute postsurgical pain was defined as a log-transformed compositional outcome of %
160 time spent in moderate – severe pain (NRS>3/10) over POD0-2. Based on area under curve for
161 repeat pain scores measured over POD0-2, % time for which pain scores were>3/10 was
162 calculated. Log-ratio transformation was applied as defined as: $f = \log(\text{average of \% time spent}$
163 $\text{in moderate or severe pain over POD0-2} / \text{average of \% time spent in mild pain over POD0-2})$.

164

165 CPSP was defined as any pain (NRS>3/10) beyond 3 months post-surgery. NRS cut-offs
166 of 3/10 depict moderate/severe pain, are associated with functional disability, and have been
167 described as a predictor for the persistence of pain [17].

168

169 2.3 Cytokine analyses

170 Cytokine levels were assayed using the Luminex multiplex (Milliplex) immunoassay
171 bead array technology. Kits from R&D Systems (LXSAHM-12) analyzed chemokine CCL22,
172 epidermal growth factor (EGF), fractalkine, IFN γ , IL-1 receptor antagonist (IL-1ra), IL-2, IL-4,
173 IL-6, IL-8, IL-10, IL-13, and TNF α levels; and Millipore Sigma (HSTCMAG28PMX13BK)
174 analyzed granulocyte-macrophage colony-stimulating factor (GM-CSF), IFN γ , IL-1 β , IL-2, IL-4,
175 IL-5, IL-6, IL-7, IL-8, IL-10, IL-12 (p70), IL-13 and TNF α levels and run according to the
176 manufacturer's protocol. See supplemental figures for sensitivity and precision. Concentrations
177 were calculated from standard curves using recombinant proteins and expressed in pg/ml using
178 Bio-Plex Manager 6.2 (Bio-Rad Laboratories, Hercules, CA).

179

180 2.4 Statistical analyses

181 Fluorescence intensities were transferred into R (<http://www.r-project.org>) statistical
182 software for converting into concentration values. Cytokine concentrations were determined
183 from the standard serial dilutions, and standard curves were obtained from the Bayesian
184 hierarchical 5-parameter logistic models created in the R package nCal [18]. Data cleaning and
185 preparation for cytokine data included several steps (weighting, normality check and log
186 transformation, winsorization, ComBat in R package sva for batch effect adjustment and
187 handling of duplicates).

188 To test if baseline cytokines was associated with acute pain or CPSP, we first conducted
189 an unadjusted analysis to determine if baseline cytokines were associated with acute pain and
190 compared values between CPSP groups using t-tests (Pooled or Satterthwaite based on the test of
191 equality of variances). We assessed the influence of covariates (age, biological sex, race, PPST,
192 surgical duration, surgery type and morphine equivalents per kg (MEQ) or confounders
193 (associated with both the independent variables and the outcomes). We then conducted multiple
194 linear or logistic regression for the log-ratio transformed acute pain and CPSP outcomes,
195 respectively, after eliminating collinear variables, and adjusting for covariates or confounders.

196 For testing if longitudinal cytokine concentration changes with time were associated with
197 pain outcomes, we computed cytokine AUC for POD0, 1 and 2 (using cytokine concentration
198 and time approximations based on blood draw timings), where cytokine AUC for POD0 was
199 standardized to 24 hours. Cytokine AUCs were log-transformed before analysis. To evaluate the
200 effect of changes in cytokine on acute pain outcome, mixed effects models with the acute pain as
201 the dependent and log transformed cytokine AUC on POD0-2 as the independent variables were
202 used. To evaluate the association between cytokine and CPSP, mixed effects models with log-

203 transformed cytokine AUC on POD0-2 as the outcome and binary CPSP as the independent
204 variable were used. POD, sex, race, surgical duration, surgery type, and total MEQ were
205 included as covariates and subjected to a random effect. We assessed for collinearity (or extreme
206 confounding) for those variables associated with the outcomes based on tolerance, variance
207 inflation factor (VIF) or generalized variance inflation factor (GVIF) for categorical variables.
208 We eliminated correlated variables in both multiple regression and mixed effects models. Results
209 from full models (supplementary material) and reduced models, where only covariates with $p \leq$
210 0.05 were retained, are presented.

211 3. Results

212 In all, 112 subjects were included in the study. Patient, surgical and outcome summary
213 statistics are provided in **Table 1**. The majority of subjects were White (97.3%) and female
214 (54.5%) and underwent pectus or spine surgeries under standardized anesthesia/pain protocols.
215 The incidence of CPSP in this cohort was 43.9%, with loss of retention in five subjects. One of
216 the cytokines, EGF, was excluded from the regression analysis because the reported
217 concentrations had the same value across all time points.

218
219 A total of 4230 cytokine concentration measures were initially included in the analyses.
220 After data cleaning, the resulting number of observations was 3334. Details of data cleaning,
221 tables of winsorized data, plots of before and after ComBat adjustment (**Supplementary Fig 1**)
222 and cytokine data by CPSP over regrouped time points (**Supplementary Fig 2**) are presented in
223 the supplementary materials. Finally, n=3249 concentrations from subjects who self-identified as
224 belonging to White and Black race were included for association analyses due to the small
225 number of subjects from other races.

226
227 3.1 Univariate associations between baseline cytokines with postoperative pain outcomes

228 Using unadjusted model, a series of simple linear regressions showed higher acute pain
229 associated with GM-CSF ($\beta=0.90$, SE 0.33, $p=.008$), IL-2 ($\beta=0.79$, SE 0.35, $p=.03$), and IL-12
230 p70 ($\beta=0.92$, SE 0.43, $p=.04$) concentrations at baseline (**Table S1**). Comparison of baseline
231 cytokines between CPSP and controls showed differences only for CCL22 (CPSP 5.90 ± 0.52
232 pg/ml vs. control 6.51 ± 0.40); $p=.004$) (**Table S2**).

233

234 3.2 Multivariate adjusted analyses: Baseline cytokines and pain outcomes

235 Biological sex, and surgery type were associated with CPSP, while MEQ was associated
236 with acute pain outcomes ($p<.05$). Participant's sex was also associated with IL-2 and MEQ with
237 IL-8 levels (acted as confounders). Thus, in models adjusted for sex, MEQ, and surgery type, a
238 series of analyses were conducted to evaluate the association of baseline cytokines with CPSP
239 and acute pain (**Table S3**). Baseline cytokine concentrations were associated with acute pain for
240 GM-CSF ($\beta=0.95$, SE 0.31; $p=.003$), IL-1 β ($\beta=0.84$, SE 0.36; $p=.02$), IL-2 ($\beta=0.78$, SE 0.34;
241 $p=.03$), and IL-12 p70 ($\beta=0.88$, SE 0.40; $p=.03$), after controlling for relevant covariates and
242 confounders (**Table 2**). In general, greater cytokine concentration levels were associated with
243 with higher MEQ ($p<.001$). After controlling for relevant covariates and confounders, baseline
244 cytokine concentrations were associated with CPSP for IL-8 ($\beta= -0.39$, SE 0.17; $p=.02$) (**Table**
245 **3**). Baseline concentrations were associated with increased odds for CPSP in female (*vs.* male)
246 sex (IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, and TNF α) and pectus (*vs.* spine) surgery patients (IL-8,
247 IL-10).

248

249 3.2 Mixed effects model: Association of cytokine concentrations over time with acute pain 250 outcome

251 Mixed effects models were also adjusted for surgical duration/type, MEQ, sex, and race.
252 In the full model, log cytokine AUC was associated with acute pain in GM-CSF ($\beta=1.38$, SE
253 0.57; $p=.03$), IFN γ ($\beta=1.36$, SE 0.6; $p=.03$), IL-1 β ($\beta=1.25$, SE 0.59; $p=.03$), IL-7 ($\beta=1.65$, SE
254 0.7; $p=.02$), and IL-12 p70 ($\beta=1.17$, SE 0.58; $p=.04$) (**Table 4**). POD, surgery type/duration and
255 MEQ were adjusted in several cytokine-acute pain association models (**Table S4**). The final
256 reduced multiple regression model revealed associations with GM-CSF, IFN γ , IL-1 β , IL-5, IL-7,

257 and IL-12 p70 ($p < .05$) after adjusting for surgical duration (**Table 4**). Estimates for an
258 association of covariates were positive except for POD2, indicating decreasing acute pain over
259 POD2.

260

261 3.4 Mixed effects model: Association of longitudinal cytokine concentrations and CPSP

262

263 Line chart of cytokine concentrations over time are provided in **Fig S2**, and the full
264 model is in **Table S5**. CPSP was significantly associated with log cytokine AUC for IL-6 ($\beta = -$
265 0.57 , SE 0.26 ; $p = .03$), IL-8 ($\beta = -0.68$, SE 0.24 ; $p = .006$), and IL-13 ($\beta = -0.48$, SE 0.22 ; $p = .03$)
266 (**Table 4**). Postoperative day and surgical duration were adjusted in the reduced model. Estimates
267 for association with log cytokine AUC were negative for pectus surgery and Black race and
268 positive for POD (POD1 and POD2) and MEQ. (**Table S5**)

269 4. Discussion

270 In this prospective study of adolescents undergoing pectus or spine deformity correction
271 surgery, cytokines were assayed from blood samples collected preoperatively and over six time
272 points over POD0-2 and week 2 after surgery. The aims were to determine associations of
273 baseline and longitudinal cytokine changes over POD0-2 with acute and chronic postoperative
274 pain, adjusted for other covariates. We identified POD, sex, MEQ and surgery type/duration as
275 covariates, as these were associated with cytokine and pain outcomes. Multivariate regression
276 models revealed that higher baseline (i.e., preoperative) levels of GM-CSF, IL-1 β , IL-2, and IL-
277 12 p70 concentrations were associated with acute pain (i.e., % time in moderate-severe pain after
278 surgery) while higher levels of baseline IL-8 decreased the odds for CPSP. Mixed effects models
279 demonstrated that longitudinal postoperative cytokine concentrations of IL-6, IL-8, and IL-13
280 were protective for CPSP (i.e. increased concentration decreased odds of developing CPSP),
281 while higher longitudinal postoperative concentrations of GM-CSF, IFN γ , IL-1 β , IL-7, and IL-12
282 p70 were associated with higher acute pain. Collectively, our data identified distinct cytokine
283 signatures that are associated with differential outcomes for acute and chronic postsurgical pain.
284 Severity of acute pain was predicted by elevations of mostly pro-inflammatory, chemotactic, and
285 proliferative cytokines, while likelihood of developing chronic pain was associated with baseline
286 and postoperative elevations of IL-6, IL-8, and IL-13, which suggest a pain-resolving mechanism
287 associated with these immune mediators.

288 The immediate postoperative period is characterized by an orchestrated release of
289 cytokines in response to surgical trauma. We found that baseline or overall AUC of GM-CSF,
290 IFN γ , IL-1 β , IL-2, IL-7, and IL-12 p70 were higher with % time in moderate-severe pain on
291 POD0-2. Several of these cytokines are known to be pro-inflammatory; some are secreted by T

292 helper cells and lead to the growth/differentiation of monocytes (GM-CSF) and proliferation of B
293 cells, T cells, and natural killer (NK) cells (IL-2, IL-7). In contrast, others are released by
294 macrophages and act on NK cells (IL-12 p70) and lead to IFN γ release, which activates
295 macrophages, neutrophils and NK cells and promotes cell-mediated immunity. IL-6 and TNF α
296 have also been implicated in sensitizing pain pathways and amplifying nociceptive signals[7].
297 However, our study did not find them to be associated with pain outcomes. This aligns with other
298 studies in adults. After hip arthroplasty serial IL-6 concentrations on POD1 were found to predict
299 disability but not pain on discharge [19]. , or long-term disability at one and six months after
300 surgery. Another study evaluating preoperative IL-6 and TNF α did not predict early pain or
301 function after total hip arthroplasty [20]. These conflicting reports suggest that individual
302 cytokine concentrations are not uniformly predictive of pain outcomes, and further work is
303 required to uncover specific determinants of inflammatory responses in the postoperative period.

304 Traditionally, cytokines such as IL-1 receptor antagonist, IL-4, IL-10, IL-11, and IL-13
305 are considered anti-inflammatory. Low blood levels of IL-4 and IL-10 were reported to be
306 associated with chronic widespread pain [21]. However, we did not find associations between IL-
307 4 or IL-10 with CPSP. We did find IL-13 to be protective for CPSP. IL-13 (and IL-4) belong to
308 the T helper 2 (Th2) cytokine family and have been shown to play a role in downmodulating
309 inflammatory responses in rheumatoid arthritis, induce macrophage polarization from a pro-
310 inflammatory M1 to an anti-inflammatory M2 phenotype [22]. Studies in mice have shown that
311 IL-13 released from T cells can polarize macrophages into an M2-like phenotype, and the
312 resulting production of anti-inflammatory cytokines from these polarized macrophages was
313 found to be critical for the resolution of chemotherapy-induced peripheral neuropathy.[23]. IL-13
314 signaling uses the JAK-signal transducer and activator of the transcription (STAT) pathway,

315 specifically STAT6 [24], and these pathways may be future intervention targets. We also found
316 baseline IL-8 and postoperative IL-8 AUC over POD0-2 to be protective for CPSP. However,
317 this is not aligned with its known pro-inflammatory role and its association with pain in other
318 studies [25]. Instead, our data support the notion that IL-8 may promote the recruitment or
319 expansion of endogenous pain-resolving immune cells [add citations]. In support of this, patients
320 with transcriptional responses associated with acute neutrophil activation after injury were less
321 likely to transition from acute to chronic lower back pain[26]. Furthermore, female sex remained
322 a significant factor associated with higher CPSP in these models. Our findings are aligned with
323 those of a study of inflammatory markers in chronic pelvic pain patients. They reported IL-8 was
324 protective with a sex-specific effect: women with pelvic pain showed a negative relationship
325 between IL-8 and widespread pain, while men did not [27]. Female sex was also a covariate for
326 AUC cytokine associations with CPSP for IL-4, IL-6, IL-8, and IL-13 cytokines. In an
327 experimental study of sex effects on lipopolysaccharide (LPS) induced immune activation,
328 visceral and musculoskeletal hyperalgesia was found to occur in both men and women,
329 irrespective of biological sex. However, the LPS-induced cytokine increases in women were
330 more pronounced [28]. Thus, future studies should investigate sex-cytokine interactions in pain
331 as a biological mechanism for sex differences in pain.

332

333 We identified postsurgical time-dependent changes in cytokine levels with increased
334 cytokine levels on POD1 followed by a decline on POD2. This is similar to the results of another
335 study in 11 patients which found that five cytokines (IL-4, IL-6, IL-10, IL-12 p70 and IL-13) in
336 plasma and ten cytokines in the cerebrospinal fluid (CSF) (IFN γ , IL-1 β , IL-2, IL-4, IL-6, IL-8,
337 IL-10, IL-12 p70, IL-13, and TNF α) rose significantly following femoral neck surgery [29].

338 However, the study did not report associations with clinical pain. Interestingly,
339 neuroinflammatory responses (in CSF) were not shown to correlate with plasma levels. This is
340 surprising as postsurgical studies in elderly patients found plasma TNF α , IL-6, and IL-10 levels
341 to be independent predictors for adverse central postoperative outcomes such as cognitive
342 deficits [30]. Future studies need to understand better the correlation of neuroinflammatory
343 markers in clinical pain cohorts.

344 Surgery type (pectus vs spine) was associated with IL-8 and IL-10 at baseline in CPSP
345 and acute pain association models. Prior research has shown similar differences with IL-6
346 increases with more major surgery (aortic vs. hernia surgery) and in those with complications
347 (N=3) [31] Opioid consumption was identified as a covariate for the association of baseline
348 cytokine as well as cytokine exposure (AUC) for several cytokines (GM-CSF, IL-1 β , IL-2-8, IL-
349 10, IL-12 p70, IL-13, TNF α) with acute pain, even when surgery type and duration were adjusted
350 for in the models.

351

352 Our findings support the hypothesis that pro-inflammatory antagonists or anti-
353 inflammatory agents could attenuate acute and chronic postsurgical pain. Our results predict that
354 pharmacological or immunomodulatory approaches to broadly inhibit circulating pro-
355 inflammatory cytokines would improve outcomes associated with acute pain, while interventions
356 to elevate IL-6, IL-8, and IL-13 in the immediate postoperative period could prevent the
357 transition from acute to chronic pain. Although it remains an ongoing challenge to suppress pain-
358 promoting inflammation while promoting pain-resolving immune responses, there is evidence
359 that immunotherapies may improve the treatment of ongoing pain[32, 33] . For example, anti-
360 TNF α agents such as etanercept have found promise in inflammatory conditions such as

361 rheumatoid arthritis [34]. Recently, IL-13 administration in mice was found to reverse
362 inflammatory macrophage-dependent neuropathic pain *via* a phenotype shift toward suppressive
363 macrophages [35]. Our results add to the evolving understanding of cytokine involvement in
364 postoperative pain, supporting emerging strategies targeting cytokine signaling to alleviate
365 postoperative pain in children. Of note, multimodal analgesia components such as intravenous
366 lidocaine and dexamethasone have been investigated for their anti-inflammatory effects and
367 potential analgesic benefits after major musculoskeletal surgeries such as spine fusion, with
368 mixed evidence regarding their benefits [36, 37].

369

370 4.1 Limitations

371 One limitation of our study is that we did not adjust statistical significance for multiple
372 tests. Despite this, to our knowledge, this might be the first study of longitudinal cytokines in
373 relation to acute and chronic post-surgical pain in a well characterized, prospective, pediatric
374 cohort. Moreover, the generalization over two surgeries makes our findings generalizable. Also,
375 although the data was analyzed in different batches, we used high rigor in normalizing and
376 analyzing the cytokine data. Despite the study's observational nature, spine and pectus surgical
377 patients received standardized protocols, minimizing differences in pain management regimens.

378

379 4.2 Conclusions

380 In conclusion, this paper describes the association between cytokines and acute and
381 chronic postoperative pain in pediatric patients. Cytokine measurements perioperatively may not
382 only serve as biomarkers and enable prediction of pain-related risk but also suggest potential

383 tailored interventions, thus paving the way for more personalized and effective pain management
384 in the pediatric surgical setting. Future studies need to elucidate sex interactions with immune
385 signaling and surgery-specific differences.

386

387 **Acknowledgments**

388 The authors gratefully acknowledge Maria E Ashton, MS, RPh, MBA, Medical Writer,
389 Department of Anesthesiology, Cincinnati Children's Hospital Medical Center, for providing
390 writing assistance, editing, and proofreading.

391 **References**

- 392 [1] Lee CS, Merchant S, Chidambaran V. Postoperative Pain Management in Pediatric Spinal Fusion
393 Surgery for Idiopathic Scoliosis. *Paediatr Drugs*. 2020;22:575-601.
- 394 [2] Rabbitts JA, Fisher E, Rosenbloom BN, Palermo TM. Prevalence and Predictors of Chronic Postsurgical
395 Pain in Children: A Systematic Review and Meta-Analysis. *J Pain*. 2017;18:605-14.
- 396 [3] Chidambaran V, Ding L, Moore DL, Spruance K, Cudilo EM, Pilipenko V, et al. Predicting the pain
397 continuum after adolescent idiopathic scoliosis surgery: A prospective cohort study. *Eur J Pain*.
398 2017;21:1252-65.
- 399 [4] Weledji EP. The role of cytokines in enhanced recovery after surgery. *IJS Short Reports*. 2021;6.
- 400 [5] Hsing C-H, Wang J-J. Clinical implication of perioperative inflammatory cytokine alteration. *Acta*
401 *Anaesthesiologica Taiwanica*. 2015;53:23-8.
- 402 [6] Bosch DJ, Nieuwenhuijs-Moeke GJ, van Meurs M, Abdulahad WH, Struys M. Immune Modulatory
403 Effects of Nonsteroidal Anti-inflammatory Drugs in the Perioperative Period and Their Consequence on
404 Postoperative Outcome. *Anesthesiology*. 2022;136:843-60.
- 405 [7] Grace PM, Hutchinson MR, Maier SF, Watkins LR. Pathological pain and the neuroimmune interface.
406 *Nat Rev Immunol*. 2014;14:217-31.
- 407 [8] Si HB, Yang TM, Zeng Y, Zhou ZK, Pei FX, Lu YR, et al. Correlations between inflammatory cytokines,
408 muscle damage markers and acute postoperative pain following primary total knee arthroplasty. *BMC*
409 *Musculoskelet Disord*. 2017;18:265.
- 410 [9] Watkins LR, Maier SF, Goehler LE. Immune activation: the role of pro-inflammatory cytokines in
411 inflammation, illness responses and pathological pain states. *Pain*. 1995;63:289-302.
- 412 [10] Gandhi R, Santone D, Takahashi M, Dessouki O, Mahomed NN. Inflammatory predictors of ongoing
413 pain 2 years following knee replacement surgery. *Knee*. 2013;20:316-8.
- 414 [11] Azim S, Nicholson J, Rebecchi MJ, Galbavy W, Feng T, Rizwan S, et al. Interleukin-6 and leptin levels
415 are associated with preoperative pain severity in patients with osteoarthritis but not with acute pain
416 after total knee arthroplasty. *Knee*. 2018;25:25-33.
- 417 [12] Narayanasamy S, Yang F, Ding L, Geisler K, Glynn S, Ganesh A, et al. Pediatric Pain Screening Tool: A
418 Simple 9-Item Questionnaire Predicts Functional and Chronic Postsurgical Pain Outcomes After Major
419 Musculoskeletal Surgeries. *J Pain*. 2022;23:98-111.
- 420 [13] Chidambaran V, Zhang X, Geisler K, Stubbeman BL, Chen X, Weirauch MT, et al. Enrichment of
421 Genomic Pathways Based on Differential DNA Methylation Associated With Chronic Postsurgical Pain and
422 Anxiety in Children: A Prospective, Pilot Study. *J Pain*. 2019;20:771-85.
- 423 [14] Vandembroucke JP, von Elm E, Altman DG, Gotzsche PC, Mulrow CD, Pocock SJ, et al. Strengthening
424 the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration.
425 *Epidemiology*. 2007;18:805-35.
- 426 [15] von Baeyer CL. Numerical rating scale for self-report of pain intensity in children and adolescents:
427 recent progress and further questions. *Eur J Pain*. 2009;13:1005-7.
- 428 [16] Simons LE, Smith A, Ibagon C, Coakley R, Logan DE, Schechter N, et al. Pediatric Pain Screening Tool:
429 rapid identification of risk in youth with pain complaints. *Pain*. 2015;156:1511-8.
- 430 [17] Gerbershagen HJ, Rothaug J, Kalkman CJ, Meissner W. Determination of moderate-to-severe
431 postoperative pain on the numeric rating scale: a cut-off point analysis applying four different methods.
432 *Br J Anaesth*. 2011;107:619-26.
- 433 [18] Fong Y, Sebestyen K, Yu X, Gilbert P, Self S. nCal: an R package for non-linear calibration.
434 *Bioinformatics*. 2013;29:2653-4.
- 435 [19] Hall GM, Peerbhoy D, Shenkin A, Parker CJ, Salmon P. Relationship of the functional recovery after
436 hip arthroplasty to the neuroendocrine and inflammatory responses. *Br J Anaesth*. 2001;87:537-42.

- 437 [20] Poehling-Monaghan KL, Taunton MJ, Kamath AF, Trousdale RT, Sierra RJ, Pagnano MW. No
438 Correlation Between Serum Markers and Early Functional Outcome After Contemporary THA. *Clin*
439 *Orthop Relat Res*. 2017;475:452-62.
- 440 [21] Uçeyler N, Valenza R, Stock M, Schedel R, Sprotte G, Sommer C. Reduced levels of antiinflammatory
441 cytokines in patients with chronic widespread pain. *Arthritis Rheum*. 2006;54:2656-64.
- 442 [22] Iwaszko M, Biały S, Bogunia-Kubik K. Significance of Interleukin (IL)-4 and IL-13 in Inflammatory
443 Arthritis. *Cells*. 2021;10.
- 444 [23] Singh SK, Krukowski K, Laumet GO, Weis D, Alexander JF, Heijnen CJ, et al. CD8+ T cell-derived IL-13
445 increases macrophage IL-10 to resolve neuropathic pain. *JCI Insight*. 2022;7.
- 446 [24] Takeda K, Kamanaka M, Tanaka T, Kishimoto T, Akira S. Impaired IL-13-mediated functions of
447 macrophages in STAT6-deficient mice. *J Immunol*. 1996;157:3220-2.
- 448 [25] Hedderson WC, Borsa PA, Fillingim RB, Coombes SA, Hass CJ, George SZ. Plasma Concentrations of
449 Select Inflammatory Cytokines Predicts Pain Intensity 48 Hours Post-Shoulder Muscle Injury. *Clin J Pain*.
450 2020;36:775-81.
- 451 [26] Parisien M, Lima LV, Dagostino C, El-Hachem N, Drury GL, Grant AV, et al. Acute inflammatory
452 response via neutrophil activation protects against the development of chronic pain. *Sci Transl Med*.
453 2022;14:eabj9954.
- 454 [27] Karshikoff B, Martucci KT, Mackey S. Relationship Between Blood Cytokine Levels, Psychological
455 Comorbidity, and Widespreadness of Pain in Chronic Pelvic Pain. *Frontiers in Psychiatry*. 2021;12.
- 456 [28] Wegner A, Elsenbruch S, Rebernik L, Roderigo T, Engelbrecht E, Jäger M, et al. Inflammation-induced
457 pain sensitization in men and women: does sex matter in experimental endotoxemia? *Pain*.
458 2015;156:1954-64.
- 459 [29] Fertleman M, Pereira C, Dani M, Harris BHL, Di Giovannantonio M, Taylor-Robinson SD. Cytokine
460 changes in cerebrospinal fluid and plasma after emergency orthopaedic surgery. *Scientific Reports*.
461 2022;12:2221.
- 462 [30] Sun T, Wang X, Liu Z, Chen X, Zhang J. Plasma concentrations of pro- and anti-inflammatory
463 cytokines and outcome prediction in elderly hip fracture patients. *Injury*. 2011;42:707-13.
- 464 [31] Baigrie RJ, Lamont PM, Kwiatkowski D, Dallman MJ, Morris PJ. Systemic cytokine response after
465 major surgery. *Br J Surg*. 1992;79:757-60.
- 466 [32] Kavelaars A, Heijnen CJ. Immune regulation of pain: Friend and foe. *Sci Transl Med*.
467 2021;13:eabj7152.
- 468 [33] Fiore NT, Debs SR, Hayes JP, Duffy SS, Moalem-Taylor G. Pain-resolving immune mechanisms in
469 neuropathic pain. *Nat Rev Neurol*. 2023;19:199-220.
- 470 [34] Hung AL, Lim M, Doshi TL. Targeting cytokines for treatment of neuropathic pain. *Scandinavian*
471 *Journal of Pain*. 2017;17:287-93.
- 472 [35] Kiguchi N, Sakaguchi H, Kadowaki Y, Saika F, Fukazawa Y, Matsuzaki S, et al. Peripheral administration
473 of interleukin-13 reverses inflammatory macrophage and tactile allodynia in mice with partial sciatic
474 nerve ligation. *Journal of Pharmacological Sciences*. 2017;133:53-6.
- 475 [36] Dewinter G, Moens P, Fieuws S, Vanaudenaerde B, Van de Velde M, Rex S. Systemic lidocaine fails to
476 improve postoperative morphine consumption, postoperative recovery and quality of life in patients
477 undergoing posterior spinal arthrodesis. A double-blind, randomized, placebo-controlled trial. *British*
478 *Journal of Anaesthesia*. 2017;118:576-85.
- 479 [37] Farag E, Ghobrial M, Sessler DI, Dalton JE, Liu J, Lee JH, et al. Effect of Perioperative Intravenous
480 Lidocaine Administration on Pain, Opioid Consumption, and Quality of Life after Complex Spine Surgery.
481 *Anesthesiology*. 2013;119:932-40.

482

483 **Figure legends**

484 Figure 1: Timeline of blood draws in relation to surgery (marked by rectangle of different shade).

485 Samples are named alphabetically and sequentially. Some samples were combined and averaged

486 based on time of draw (BC and DE). * indicates they were drawn only for spine surgery subjects.

487 # indicates they were drawn only for pectus surgery subjects, due to differences in protocols and

488 to gather more samples. POD: Postoperative day; PACU: Postoperative care unit.

489

490

491

492

493

494

495

496

497

498

499

500

501

502 Table 1: Characteristics of study participants (n=112) and variables

503

Variable	Category	Mean (SD) or Median (IQR) (n=112)	Min, Max	Missing (%)
Age		15.3 (13.5, 17.0) [n=112]	9.2, 36.4	0 (0.0)
Sex	Female	61 (54.5)		0 (0.0)
	Male	51 (45.5)		
Race	Black	3 (2.7)		0 (0.0)
	White	109 (97.3)		
Surgical duration (minutes)		147.5 (90.5, 224.0) [n=112]	58.0, 383.0	0 (0.0)
Surgery	pectus	67 (59.8)		0 (0.0)
	spine	45 (40.2)		
PPST		1.0 (0.0, 3.0) [n=77]	0.0, 9.0	35 (31.3)
MEQ POD0-2		1.0 (0.7, 1.4) [n=112]	0.1, 4.1	0 (0.0)
CPSP	No	60 (56.1)		5 (4.5)
	Yes	47 (43.9)		
Acute pain POD0-2		0.1 (-0.9, 1.2) [n=104]	-8.5, 8.5	8 (7.1)

504 Note: Acute pain is presented as a: log transformed percentage time in moderate-severe pain : log(average

505 % Time in mod/severe pain on POD0-2 / average %Time in mild pain POD0-2)

506 PPST: Pediatric Pain Screening Tool

507 MEQ: Morphine equivalents/kg; POD: Postoperative day

508 CPSP: Chronic postsurgical pain

509

510

511

512

513

514

515

516

517

518

519

520

521

522

523 Table 2: Regression analysis of cytokine log concentration levels at baseline and acute pain (log
 524 transformed pain AUC over POD0-1)

Cytokine	Parameter with Relevant Covariates	Estimate	StdErr	p-value
CCL22	Log concentration	-1.65	1.33	0.225
Fractalkine	Log concentration	-1.89	2.30	0.419
	<i>Covariate: Race (Black vs. White)</i>	2.69	4.11	0.519
GM-CSF	Log concentration	0.95	0.31	0.003
	<i>Covariate: MEQ, POD0-2</i>	1.67	0.41	<0.001
IFN γ	Log concentration	0.43	0.43	0.315
	<i>Covariate: MEQ, POD0-2</i>	1.43	0.40	<0.001
IL-10	Log concentration	0.13	0.25	0.586
	<i>Covariate: MEQ, POD0-2</i>	1.93	0.50	<0.001
	<i>Covariate: Surgery (Pectus vs. Spine)</i>	0.61	0.61	0.318
IL-12P70	Log concentration	0.88	0.40	0.031
	<i>Covariate: MEQ, POD0-2</i>	1.58	0.41	<0.001
IL-13	Log concentration	0.11	0.21	0.602
	<i>Covariate: MEQ, POD0-2</i>	1.27	0.40	0.002
IL-1B	Log concentration	0.84	0.36	0.023
	<i>Covariate: MEQ, POD0-2</i>	1.75	0.43	<0.001
IL-1ra	Log concentration	-0.16	2.01	0.937
IL-2	Log concentration	0.78	0.34	0.026
	<i>Covariate: Sex (Female)</i>	-0.55	0.53	0.303
	<i>Covariate: MEQ, POD0-2</i>	1.38	0.40	<0.002
IL-4	Log concentration	-0.18	0.25	0.485
	<i>Covariate: MEQ, POD0-2</i>	1.04	0.35	0.004
IL-5	Log concentration	0.17	0.27	0.535
	<i>Covariate: MEQ, POD0-2</i>	1.51	0.41	<0.001
IL-7	Log concentration	0.50	0.46	0.276
	<i>Covariate: MEQ, POD0-2</i>	1.60	0.42	<0.001
IL-8	Log concentration	0.23	0.19	0.213
	<i>Covariate: MEQ, POD0-2</i>	1.39	0.42	0.001
	<i>Covariate: Surgery (Pectus)</i>	0.44	0.57	0.439
TNF α	Log concentration	0.11	0.71	0.875
	<i>Covariate: MEQ, POD0-2</i>	1.07	0.36	0.004

525 Significant p-values (<.05) bolded for covariates and cytokine associations, with those for cytokine
 526 associations are marked in red text. MEQ: Morphine equivalents/kg; POD: postoperative day

527

528

529

530 Table 3: Regression analysis of baseline cytokine concentrations with risk (Odds) of developing chronic
 531 postsurgical pain (CPSP)

Cytokine	Parameter with relevant covariates	Odds Ratio (95% CI)	Estimate β	Std Error	P -value
CCL22	Log concentration	0.20 (0.03 - 1.47)	-1.62	1.02	0.114
Fractalkine	Log concentration	0.89 (0.09 - 8.71)	-0.12	1.17	0.918
GM_CSF	Log concentration	1.35 (0.78 - 2.36)	0.30	0.28	0.285
GM_CSF	Covariate: Sex (Female vs. Male)	2.25 (1.00 - 5.09)	0.41	0.21	0.051
IFN γ	Log concentration	1.29 (0.59 - 2.81)	0.25	0.40	0.529
IFN γ	Covariate: Sex (Female vs. Male)	2.19 (0.97 - 4.94)	0.39	0.21	0.059
IL-10	Log concentration	0.78 (0.50 - 1.20)	-0.25	0.22	0.259
IL-10	Covariate: Sex (Female vs. Male)	4.27 (1.49 - 12.26)	0.73	0.27	0.007

532

IL-10	Covariate: Surgery (pectus vs spine)	3.55 (1.15 - 10.91)	0.63	0.29	0.027
IL-12P70	Log concentration	1.07 (0.54 - 2.15)	0.07	0.35	0.840
IL-12P70	Covariate: Sex (Female vs. Male)	2.23 (0.98 - 5.07)	0.40	0.21	0.055
IL-13	Log concentration	0.79 (0.56 - 1.10)	-0.24	0.17	0.158
IL-13	Covariate: Sex (Female vs. Male)	2.35 (1.03 - 5.36)	0.43	0.21	0.042
IL-1B	Log concentration	1.29 (0.72 - 2.30)	0.25	0.30	0.396
IL-1ra	Log concentration	0.48 (0.05 - 4.65)	-0.74	1.16	0.525
IL-2	Log concentration	1.23 (0.70 - 2.17)	0.21	0.29	0.468
IL-2	Covariate: Sex (Female vs. Male)	2.46 (1.07 - 5.66)	0.45	0.21	0.034
IL-4	Log concentration	0.91 (0.59 - 1.39)	-0.10	0.22	0.646
IL-4	Covariate: Sex (Female vs. Male)	2.63 (1.17 - 5.92)	0.48	0.21	0.020
IL-5	Log concentration	0.84 (0.54 - 1.30)	-0.17	0.22	0.438
IL-5	Covariate: Sex (Female vs. Male)	2.43 (1.07 - 5.55)	0.44	0.21	0.035
IL-6	Log concentration	0.82 (0.63 - 1.06)	-0.20	0.13	0.132
IL-6	Covariate: Sex (Female vs. Male)	3.09 (1.16 - 8.23)	0.56	0.25	0.024
IL-7	Log concentration	1.20 (0.54 - 2.67)	0.18	0.41	0.655
IL-7	Covariate: Sex (Female vs. Male)	2.19 (0.96 - 4.99)	0.39	0.21	0.064
IL-8	Log concentration	0.68 (0.48 - 0.95)	-0.39	0.17	0.023
IL-8	Covariate: Sex (Female vs. Male)	6.13 (1.98 - 18.92)	0.91	0.29	0.002
IL-8	Covariate: Surgery (pectus vs spine)	5.53 (1.55 - 19.71)	0.86	0.32	0.009
IL-8	Covariate: MEQ POD0-2	1.20 (0.58 - 2.45)	0.18	0.37	0.627
TNF α	Log concentration	0.66 (0.20 - 2.25)	-0.41	0.62	0.510
TNF α	Covariate: Sex (Female vs. Male)	2.45 (1.10 - 5.48)	0.45	0.21	0.029

533 Significant p-values (<.05) bolded for covariates and cytokine associations, with those for cytokine – pain
534 associations marked in red text. MEQ: Morphine equivalents/kg; POD: postoperative day

535

536

537

538

539

540

541 Table 4. Mixed effects model (reduced model) results for significant associations of pain
542 outcomes and covariates with cytokine concentrations over POD0-2, adjusted for surgical
543 duration.

Dependent variable: Acute pain (Log transformed %time moderate-severe pain over POD0-2)		
Cytokine	Outcome: Cytokine AUC over POD0-2 Estimate (SE); P-value	Covariate: MEQ POD0-2 association with log cytokine AUC P-value
CCL22		
Fractalkine		
GM-CSF	1.38 (.57); .02	-
IFN γ	1.36 (.6); .03	-
IL-10		
IL-12P70	1.17 (.58); .04	-

IL-13						
IL-1B	1.25 (.59); .03				.04	
IL-1ra						
IL-2						
IL-4						
IL-5	-				.03	
IL-6						
IL-7	1.65 (.7); .02				-	
IL-8						
TNF α						
Dependent variable: Log Cytokine AUC over POD0-2; Association with chronic post-surgical pain (CPSP)						
Cytokine	Outcome: CPSP Estimate (SE); P-value	P-values for Covariate associations with Cytokine AUC				
		POD	Surgical duration	Sex	Race	MEQ
CCL22					.04	
Fractalkine						
GM-CSF		<.001				
IFN γ		<.001				.008
IL-10		<.001	.04	.02		
IL-12P70		<.001				
IL-13	-0.48 (0.22); .03	<.001		.005		
IL-1B		<.001				
IL-1ra		<.001				
IL-2		<.001		.01		<.001
IL-4		<.001		.004		
IL-5		<.001		.04		
IL-6	-0.57 (0.26); .03	<.001		.003		
IL-7		<.001	.004			
IL-8	-0.68 (0.24); .006	<.001		.004		
TNF α		<.001	<.001			.002

544

545

